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Abstract
The aim was to examine the association of patient-reported physician awareness of biological CAM use and patient percep-
tions of care experience and quality with a population-based study of patients with incident lung and colorectal cancer. This
was a secondary data analysis using regression models. Outcomes of interest were patient reports of medical care experience
and quality ratings. Among 716 patients who reported biological CAM use, 69% reported their physicians were aware of this.
Patients who reported physician awareness of biological CAM use had higher adjusted scores for medical care experience
(+ 5.4, 95%CI:2.3,8.6) and care quality (+ 3.6, 95%CI:−0.3,+ 7.5). These associations suggest that physicians should be
encouraged to inquire about biological CAM use.
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Introduction
Patients with cancer frequently use complementary and alter-
native medicines (CAM), (1) which refers to “medical prod-
ucts and practices that are not part of standard medical
care.” (2) The term CAM encompasses practices such as
yoga and massage as well as biological products including
vitamins, supplements, and botanicals including herbs (hence-
forth “biological CAM”). (2) Use of CAM by patients with
cancer ranges from 11–95%, (3) and reasons for use include
managing treatment side effects. (2) A study of patients who
recently completed chemotherapy found that 51% reported
the use of biological CAM during treatment. (4)
Communication regarding biological CAM is especially
important in the oncology setting, as these products may inter-
act with anti-cancer therapies. (5) Interactions were considered
likely to occur for approximately 37% of patients with cancer
using CAM in a German study. (6) Decreased efficacy of anti-
cancer therapies is also a concern; for example, St John’s Wort
may impact the efficacy of anti-cancer therapies. (2)
Although communication is important, 20–77% of
patients using CAM may not discuss their use of it with
health professionals. (3) When communication does occur
it appears beneficial: oncology consultations involving such
communication are longer and more patient-centered. (7,8)
However, these studies focused on a few practices in specific
geographic areas of the US, and the generalizability of these
results is therefore unclear.
The question of this association is especially relevant as
patient-reported experience measures (PREMs) are of
1 Menzies Institute for Medical Research, University of Tasmania, Hobart,
TAS, Australia
2 Department of Health Services, Policy, and Practice, Brown University
School of Public Health, Providence, RI, USA
3 Department of Biostatistics, Brown University School of Public Health,
Providence, RI, USA
4 Department of Epidemiology, College of Public Health, The University of
Iowa, Iowa City, IA, USA
5 Division of Oncology Products, US Food and Drug Administration, Silver
Spring, MD, USA
6 Department of Health Care Policy, Harvard Medical School, Boston MA,
USA
7 Division of General Internal Medicine, Brigham and Women’s Hospital,
Boston MA, USA
Corresponding Author:
Jessica K. Roydhouse, Menzies Institute for Medical Research, University of
Tasmania, 17 Liverpool Street, Hobart TAS Australia 7000, USA.
Email: jessica.roydhouse@utas.edu.au
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0
License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further
permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Patient Experience Research Briefs
Journal of Patient Experience
Volume 8: 1-5





increasing interest, particularly in the oncology setting.
Recently, a cancer care-specific Consumer Assessment of
Healthcare Providers and Systems (CAHPS) survey was
developed; CAHPS is a widely used measurement system
for patient experience in the US. (9) CAHPS surveys are pub-
licly reported and play an important role in quality improve-
ment. (10) We sought to examine the association of patient
reports of physician awareness of biological CAM and
patient reports and ratings of care and experience and
quality using cross-sectional data from a population-based
study of patients with incident lung and colorectal cancer
in the US. Among patients who reported using biological
CAM, we evaluated if 1) patient reports of medical care expe-
rience and 2) ratings of care quality differed based on patient
reports of physician awareness of biological CAM use.
Method
We used data from the Cancer Care Outcomes Research and
Surveillance (CanCORS) study, a large, population-based
study of patients with incident lung and colorectal cancer.
(11) The data collection (11) and analytic (12) approaches
for CanCORS have been described previously. Briefly,
CanCORS collected data from approximately 10,000 patients
with incident lung or colorectal cancer diagnosed between
2003 and 2005. Patients aged ≥21 years were identified
using rapid case ascertainment and enrolled from geographic
areas (including Alabama, Iowa, California, and North
Carolina) and health systems (including the Veterans
Health Administration) across the United States. (11) Over
half of CanCORS patients were age 65 or older. (11)
CanCORS patients were similar to patients in Surveillance,
Epidemiology and End Results areas with new onset lung
and colorectal cancer during the same period. (13) A
computer-assisted telephone interview was used to survey
patients in English, Spanish or Chinese. (11) The survey
included questions about patient health, demographics and
perceptions of care experience and quality. (14) The
CanCORS study was approved by human subjects research
committees (IRBs) at all participating institutions and
informed consent was obtained from participating patients.
For this study, we used data from patients who were alive
and completed the CanCORS full baseline survey (conducted
a median of 5 months after diagnosis) and also answered
“yes” to the question, “Since you were diagnosed with
[lung or colorectal cancer], have you taken any herbal rem-
edies or other supplements to treat your cancer or boost
your immune system?”
Patients who reported using biological CAM were asked
to name the products they used. For up to three products
interviewers then asked: “Is your doctor aware that you are
using this therapy?” A positive response to this question
was categorized as “physician awareness.”
We focused on two outcomes: medical care experience
and care quality. Medical care experience was measured
using a five-item scale adapted from CAHPS. (11,14) The
five items evaluated how often “your doctors”: (1) listened
carefully, (2) explained things in an understandable way,
(3) gave as much information as desired about cancer treat-
ments, including potential benefits and side effects, (4)
encouraged asking questions, and (5) treatment was with
courtesy and respect. For each item, the available response
options were “always/usually/sometimes/never;” patients
could also answer “don’t know;” however, these responses
were not included in the total score. Consistent with previous
analyses, we transformed the care experience score to a 0
−100 point scale (worst-best). (11) Although the primary
outcome was the care experience score, we also evaluated
each item in the score individually. Quality was assessed
by a single question: “Overall, how would you rate the
quality of your health care since your diagnosis;” response
options included “excellent/very good/good/fair/poor.” This
was transformed to a 0-100 (worst-best) score for consis-
tency. As a sensitivity analysis, we also dichotomized all out-
comes (100; always)/not top-box; this approach has been
used with CAHPS because patient ratings tend to be highly
positively skewed. (15)
Based on a review of the literature, we also sought to
account for covariates that might affect patient report of
their care and experience, as well as those associated with
biological CAM use. These included disease stage, cancer
type, survey language, race/ethnicity, age, educational attain-
ment, gender, smoking history, health status, wealth and prior
use of the biological CAMs discussed. We used two ques-
tions for health status that covered both general and mental
health because these covariates are used when analyzing
care experience data for surveys such as CAHPS; (16) both
were drawn from the SF-12. (14)
We conducted univariable and multivariable linear regres-
sion analyses to evaluate the association of interest, adjusting
for covariates. Each outcome was modeled separately. We
also conducted analyses examining the association of interest
at the item level for each item of the medical care experience
scale. Logistic regression models were used for the sensitiv-
ity analysis. Multiple imputation (MI) was used for missing
data; the imputation approach for CanCORS has been
described previously. (12) Analyses were conducted in
SAS (v9.4) and Stata (v16.0). Modeling assumptions were
checked by examination of the residuals for linear regression
and the Hosmer-Lemeshow test for logistic regression.
Because of the use of MI, assumptions checking was imple-
mented in each imputed dataset.
Results
Sociodemographic Characteristics
Of the 716 patients who reported using biological CAM
(∼13% of the patients who completed the full baseline
survey), nearly half (47%) were 59 years of age or
younger. Most patients (69%, (n= 496)) reported that their
physicians were aware of their biological CAM use (Table 1).
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Unadjusted Analyses
In unadjusted linear regression analyses, there was a positive
association between patient reports of physician awareness of
herbal product use and medical care experience (scores+ 7.6
points on average, 95% CI: 4.4, 10.7) and care quality (scores
+ 6.4 points on average, 95% CI: 2.6, 10.3) (Table 2). This
was also seen for top-box scores (Table 2). At the item
level, all associations were positive.
Adjusted Analyses
In adjusted linear regression analyses, the differences were
attenuated (Table 2). Patients who reported physician aware-
ness of biological CAM use had adjusted medical care expe-
rience scores that were+ 5.4 points higher on average (95%
CI 2.3, 8.6). Adjusted scores for care quality were+ 3.6
points higher on average and the confidence interval included
zero (95% CI −0.3,+ 7.5). For both outcomes, similar trends
were observed for the top-box scores (Table 2).
At the item level, the associations remained positive but
were smaller in most cases and the confidence intervals for
two items contained zero. The association was strongest for
the items relating to physician provision of information and
encouragement of questions. For these two items, patients
who reported physician awareness of biological CAM use
had adjusted scores that were on average+ 0.3 points
higher (95% CI 0.1, 0.4) on a 4-point scale (Table 2).
Similar trends were seen for the top-box scores (Table 2).
Discussion
Our findings of a positive association between patient reports
of physician awareness of biological CAM use and patient-
reported medical care experience and care quality are consis-
tent with other studies. A recent study of patients with breast
and prostate cancer receiving treatment in academic centers
found that 64% of patients using biological CAM discussed
this with their oncologists, (4) similar to the 69% of patients
in this study who reported physician awareness. In that study,
34% of patients felt the discussion of biological CAM posi-
tively affected communication. (4) Our findings for the
care experience items are consistent with this. In another
oncology study, patient satisfaction scores were higher for
visits that discussed CAM compared to those that did not.
(7) Although experience and satisfaction are not equivalent,
Table 1. Characteristics of Patients who Report Biological CAM
Use: Observed Data (N= 716).
Characteristic N (%)
Age
≤59 years of age 336 (47%)
60-69 years of age 181 (25%)
70-79 years of age 155 (22%)
80+ years of age 44 (6%)
Female 379 (53%)
Education
<High school 83 (12%)










Feeling calm and peaceful
All of the time 132 (18%)
Most of the time 310 (43%)
Some of the time 184 (26%)
A little of the time 76 (11%)







Potentially curable 474 (66%)
Unstaged 34 (5%)
CanCORS site
5 integrated delivery systems 160 (22%)
8 counties in Northern CA 171 (24%)
State of Alabama 30 (4%)
Los Angeles County 174 (24%)
State of Iowa 50 (7%)
23 counties in North Carolina 67 (9%)












Current smoker 65 (9%)
Never smoker 249 (35%)
Wealth (ability to live on current savings)
<1 month 129 (18%)
1 – 2 months 87 (12%)




7 – 12 months 70 (10%)
>1 year 261 (36%)
Missing 85 (12%)
Physician is aware of biological CAM use 496 (69%)
Used biological CAM in the year prior to diagnosis 229 (32%)
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this does indicate that our findings are consistent with the
literature.
This study had several strengths. As noted, it is one of the
few population-based studies that evaluates the association
between patient-reported physician awareness of biological
CAM use and patient reports of care experience and ratings
of care quality. This assessment is particularly important
for newly diagnosed patients given the potential for biologi-
cal CAM to interact with anti-cancer treatments. Thus,
despite the age of the data the findings are relevant.
Furthermore, the use of measures similar to those in
CAHPS makes these findings highly relevant as PREMs con-
tinue to expand in oncology and a cancer-specific CAHPS
has been developed. These positive associations suggest
that physicians should be encouraged to inquire about biolog-
ical CAM use.
Limitations
A limitation of this study is that the CanCORS data were col-
lected several years ago and this cross-sectional study may
therefore not reflect current use of and communication
regarding biological CAM among patients with cancer. It
also did not ask specifically about marijuana/cannabis prod-
ucts, which are increasingly available in recent years.
Second, the question about biological CAM in the study
did not separate ‘herbal remedies’ from ‘other supplements’;
as not all supplements may be biological, it is possible that
our sample is not limited to patients using biological CAM.
Third, our cross-sectional analysis only permitted the assess-
ment of an association rather than a causal relationship.
Furthermore, we do not know if physician awareness was a
result of doctors asking patients about biological CAM use,
or if patients volunteered the information in the absence of
physician inquiry. Our assessment of physician awareness
is indirect, as it is reported by patients rather than physicians.
Finally, the question about physician awareness referred to
“your doctor,” the questions about medical care experience
referred to “your doctors,” and the question about care
quality referred to “the quality of your health care.” As
many professionals are involved in cancer care, it is possible
that patients may have interpreted these questions as referring
to different physicians.
Ethical Approval
Approvals were obtained from the Dana-Farber Cancer Institute, the
site of the CanCORS Statistical Coordinating Center
(2002-P-000196) as well as each Primary Data Collection
Research (PDCR) site.
Statement of Human and Animal Rights
All procedures in this study were conducted in accordance with
CanCORS IRB protocols.
Statement of Informed Consent
Participants at 2 PDCR sites provided written informed consent. The
other site IRBs waived this requirement, and verbal informed
consent was obtained.
Table 2. Unadjusted and Adjusted + Association of Patient Reports
of Physician Awareness of Biological CAM Use Among Users with










Care experience 7.6 (4.4 to 10.7) 5.4 (2.3 to 8.6)
Quality rating 6.4 (2.6 to 10.3) 3.6 (-0.3 to 7.5)
Care Experience Items
Item 1. Listened carefully to
you
0.2 (0.1 to 0.3) 0.1 (-0.008 to
0.2)
Item 2. Explained things in a
way you could understand
0.2 (0.04 to 0.3) 0.1 (-0.03 to
0.2)
Item 3. Gave you as much
information as you wanted
about your cancer
treatments, including
potential benefits and side
effects
0.3 (0.2 to 0.5) 0.3 (0.1 to 0.4)
Item 4. Encouraged you to
ask all the cancer-related
questions you had
0.4 (0.2 to 0.5) 0.3 (0.1 to 0.4)
Item 5. Treated you with
courtesy and respect
0.1 (0.04 to 0.2) 0.1 (0.02 to 0.2)
Logistic Models (Sensitivity
Analysis)





Top care experience 2.0 (1.4 to 2.8) 1.9 (1.3 to 2.7)
Top quality rating 1.5 (1.1 to 2.1) 1.3 (0.9 to 1.9)
Care Experience Items
Item 1. Listened carefully to
you
1.7 (1.2 to 2.4) 1.6 (1.1 to 2.4)
Item 2. Explained things in a
way you could understand
1.8 (1.3 to 2.5) 1.6 (1.1 to 2.3)
Item 3. Gave you as much
information as you wanted
about your cancer
treatments, including
potential benefits and side
effects
2.2 (1.5 to 3.0) 2.0 (1.4 to 2.8)
Item 4. Encouraged you to
ask all the cancer-related
questions you had
2.2 (1.6 to 3.1) 1.8 (1.3 to 2.7)
Item 5. Treated you with
courtesy and respect
n/a¶ n/a¶
+Adjusted for: age, sex, education, general health status, mental health status,
survey language, disease stage, CanCORS site, cancer type, race/ethnicity,
smoking history, wealth, and prior use of biological CAM; ¶Could not model
with logistic regression as too few respondents gave <top score.
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